Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
IGXT's Cash to Debt is ranked higher than
84% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. IGXT: No Debt )
IGXT' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: No Debt

Equity to Asset 0.88
IGXT's Equity to Asset is ranked higher than
90% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IGXT: 0.88 )
IGXT' s 10-Year Equity to Asset Range
Min: -0.4   Max: 0.9
Current: 0.88

-0.4
0.9
Interest Coverage No Debt
IGXT's Interest Coverage is ranked higher than
61% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IGXT: No Debt )
IGXT' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 42.58
M-Score: -2.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -220.45
IGXT's Operating margin (%) is ranked higher than
66% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. IGXT: -220.45 )
IGXT' s 10-Year Operating margin (%) Range
Min: -855   Max: -87.43
Current: -220.45

-855
-87.43
Net-margin (%) -218.20
IGXT's Net-margin (%) is ranked higher than
66% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. IGXT: -218.20 )
IGXT' s 10-Year Net-margin (%) Range
Min: -630   Max: -131.86
Current: -218.2

-630
-131.86
ROE (%) -45.16
IGXT's ROE (%) is ranked higher than
71% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. IGXT: -45.16 )
IGXT' s 10-Year ROE (%) Range
Min: -1461.46   Max: -45.62
Current: -45.16

-1461.46
-45.62
ROA (%) -37.84
IGXT's ROA (%) is ranked higher than
70% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. IGXT: -37.84 )
IGXT' s 10-Year ROA (%) Range
Min: -193.99   Max: -31.59
Current: -37.84

-193.99
-31.59
ROC (Joel Greenblatt) (%) -316.22
IGXT's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. IGXT: -316.22 )
IGXT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -809.24   Max: -150.21
Current: -316.22

-809.24
-150.21
Revenue Growth (3Y)(%) -20.60
IGXT's Revenue Growth (3Y)(%) is ranked higher than
67% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. IGXT: -20.60 )
IGXT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 35.7
Current: -20.6

0
35.7
EBITDA Growth (3Y)(%) -27.90
IGXT's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. IGXT: -27.90 )
IGXT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 122.4
Current: -27.9

0
122.4
EPS Growth (3Y)(%) -30.70
IGXT's EPS Growth (3Y)(%) is ranked higher than
62% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. IGXT: -30.70 )
IGXT' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 141
Current: -30.7

0
141
» IGXT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IGXT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 20.75
IGXT's Forward P/E is ranked higher than
96% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. IGXT: 20.75 )
N/A
P/B 11.10
IGXT's P/B is ranked higher than
67% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. IGXT: 11.10 )
IGXT' s 10-Year P/B Range
Min: 4   Max: 117
Current: 11.1

4
117
P/S 52.63
IGXT's P/S is ranked higher than
70% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. IGXT: 52.63 )
IGXT' s 10-Year P/S Range
Min: 6.25   Max: 98.5
Current: 52.63

6.25
98.5
EV-to-EBIT -19.46
IGXT's EV-to-EBIT is ranked higher than
56% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. IGXT: -19.46 )
IGXT' s 10-Year EV-to-EBIT Range
Min: -34.1   Max: -2.1
Current: -19.46

-34.1
-2.1
Current Ratio 7.58
IGXT's Current Ratio is ranked higher than
83% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. IGXT: 7.58 )
IGXT' s 10-Year Current Ratio Range
Min: 0.66   Max: 11.6
Current: 7.58

0.66
11.6
Quick Ratio 7.58
IGXT's Quick Ratio is ranked higher than
84% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. IGXT: 7.58 )
IGXT' s 10-Year Quick Ratio Range
Min: 0.66   Max: 11.6
Current: 7.58

0.66
11.6
Days Sales Outstanding 19.41
IGXT's Days Sales Outstanding is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. IGXT: 19.41 )
IGXT' s 10-Year Days Sales Outstanding Range
Min: 55.44   Max: 390.59
Current: 19.41

55.44
390.59

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.80
IGXT's Price/Net Cash is ranked higher than
81% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. IGXT: 13.80 )
IGXT' s 10-Year Price/Net Cash Range
Min: 5.33   Max: 32.25
Current: 13.8

5.33
32.25
Price/Net Current Asset Value 13.80
IGXT's Price/Net Current Asset Value is ranked higher than
80% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. IGXT: 13.80 )
IGXT' s 10-Year Price/Net Current Asset Value Range
Min: 5.33   Max: 105
Current: 13.8

5.33
105
Price/Tangible Book 10.40
IGXT's Price/Tangible Book is ranked higher than
72% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. IGXT: 10.40 )
IGXT' s 10-Year Price/Tangible Book Range
Min: 4   Max: 95
Current: 10.4

4
95
Price/Median PS Value 4.20
IGXT's Price/Median PS Value is ranked higher than
70% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. IGXT: 4.20 )
IGXT' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 4.43
Current: 4.2

0.32
4.43
Earnings Yield (Greenblatt) -5.10
IGXT's Earnings Yield (Greenblatt) is ranked higher than
74% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. IGXT: -5.10 )
IGXT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6.1   Max: 0
Current: -5.1

-6.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:IGX.Canada,
IntelGenx Technologies Corp. is a drug delivery company, that develops novel oral immediate release and controlled-release products for the branded and generic pharmaceutical market.
» More Articles for IGXT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
2015-02-23 IntelGenx Provides Update on Sales of Forfivo XL(R) Feb 23 2015
IntelGenx Provides Update on Sales of Forfivo XL(R) Feb 23 2015
IntelGenx to Present at the 8th Annual OneMedForum Jan 05 2015
IntelGenx Grants Stock Options Dec 08 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Dec 02 2014
2014-12-01 IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing... Dec 02 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Dec 01 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Nov 26 2014
2014-11-25 IntelGenx Announces Settlement of U.S. Patent Litigation Related to Forfivo XL(R) Nov 25 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Nov 25 2014
INTELGENX TECHNOLOGIES CORP. Financials Nov 21 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Nov 18 2014
2014-11-12 IntelGenx Reports Q3, 2014 Results and Provides Corporate Development Update Nov 12 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 10-Q, Quarterly Report Nov 12 2014
Small Cap Traders Delivers Brief Report: IntelGenx Technologies Corporation Targeting Better... Nov 06 2014
2014-11-03 IntelGenx Announces Successful Clinical Study for Schizophrenia Nov 03 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Nov 03 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Oct 02 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Oct 01 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Sep 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK